Generics BulletinBiosimilar launches such as ustekinumab in the US market have helped drive up growth for Samsung Bioepis in the first quarter of 2025, the Korean company has reported. With parent company Samsung Biol
Generics BulletinSamsung Bioepis has been a pioneer in the US biosimilar market since its first biosimilar Renflexis (infliximab-abda) was approved by the US Food and Drug Administration in 2017, but expensive develop
Generics BulletinTeva has launched its partner Samsung Bioepis’ Epysqli (eculizumab-aagh) injection for intravenous use biosimilar to AstraZeneca’s Soliris in the US, marking the second rival to the rare diseases trea
ScripSamsung Bioepis has been a pioneer in the US biosimilar market since its first biosimilar Renflexis (infliximab-abda) was approved by the US Food and Drug Administration in 2017, but expensive develop